<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00496821</url>
  </required_header>
  <id_info>
    <org_study_id>ALN-RSV01-105</org_study_id>
    <nct_id>NCT00496821</nct_id>
  </id_info>
  <brief_title>Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Virus</brief_title>
  <official_title>A Study to Investigate the Safety and Efficacy of Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Virus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alnylam Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alnylam Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, tolerability and efficacy of intranasal
      ALN-RSV01 versus placebo, administered once daily for 5 days to a healthy male volunteers
      experimentally inoculated with RSV
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of intranasal ALN-RSV01 versus placebo, administered in a multiple-dose schedule (once daily for 5 days) to healthy adult volunteers experimentally inoculated with respiratory syncytial virus</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determining the impact of ALN-RSV01 on symptoms of RSV infection, RSV infection rate based upon measures of viral load, and understanding the potential antiviral activity of ALN-RSV01</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Respiratory Syncytial Virus Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALN-RSV01</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Availability for the required study period (including the inpatient phase, ability to
             comply with study requirements and attend follow-up study visits

          -  Able to provide written consent for participation after reading the Consent Form and
             after having adequate opportunity to discuss the study with an investigator or
             qualified deputy.

          -  Good general health status as determined by a screening evaluation no greater than 120
             days but not less than 14 days prior to enrollment and admission to the research unit

          -  Low titers of RSV neutralizing antibody measured during screening.

        Exclusion Criteria:

          -  Significant acute or chronic, uncontrolled medical illness

          -  Presence of household member or close contact to someone who:

               -  Is less than three(3) years of age

               -  Has a known immunodeficiency

               -  Is receiving immunosuppressant drugs

               -  Is undergoing or soon to undergo cancer chemotherapy within 28 days of enrollment

               -  Has diagnosed emphysema, chronic obstructive pulmonary disease(COPD), or severe
                  lung disease

               -  Is elderly and residing in a nursing home, or

               -  Has received an organ transplant

          -  Females are not eligible for this study

          -  Evidence of or history of drug or alcohol abuse (within the past 6 months) or positive
             urine drug or alcohol screen

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Akshay Vaishnaw, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Alnylam Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alnylam Pharmaceuticals</name>
      <address>
        <city>Cambridge</city>
        <state>Massachusetts</state>
        <zip>02142</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2007</study_first_submitted>
  <study_first_submitted_qc>July 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2007</study_first_posted>
  <last_update_submitted>November 29, 2007</last_update_submitted>
  <last_update_submitted_qc>November 29, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2007</last_update_posted>
  <keyword>Respiratory Syncytial Virus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

